3 Key Takeaways
Plain English Summary- 01Core Finding
Reprogrammed tumor cells into cDC1-like cells remodeled the tumor microenvironment and induced immunogenic TLSs (imgTLSs) across melanoma, colon, bladder, breast, and pancreatic cancer models with distinct genetic backgrounds. cDC1-like cells activated lymphotoxin, TNF, and interferon (an immune-signaling protein) programs and engaged early with T cells through MHC class I and CD40 signaling to induce imgTLSs containing BCL6 + germinal centers, independently of endogenous cDC1s.
- 02Study Evidence
Tested in a in vivo animal model (preclinical discovery) at the preclinical stage.
- 03Practical Meaning
Early laboratory or animal model findings — human trials are still needed to confirm safety and benefit.
What This Means for You
ImgTLSs sustained B and T cell responses and promoted systemic immunity through expansion of shared clonotypes in distant, untreated tumors. Our findings outline the spatial organization, signaling programs and interactions of cDC1-like cells that initiate intratumoral lymphoid structures and establish cellular reprogramming as a strategy toward overcoming resistance to immunotherapy.
The Discovery
Tertiary lymphoid structures (TLSs) in tumors are associated with improved responses to immunotherapy. Here, we examined the impact of type 1 conventional dendritic cells (cDC1s) in TLS formation. Reprogrammed tumor cells into cDC1-like cells remodeled the tumor microenvironment and induced immunogenic TLSs (imgTLSs) across melanoma, colon, bladder, breast, and pancreatic cancer models with distinct genetic backgrounds. cDC1-like cells activated lymphotoxin, TNF, and interferon (an immune-signaling protein) programs and engaged early with T cells through MHC class I and CD40 signaling to induce imgTLSs containing BCL6 + germinal centers, independently of endogenous cDC1s. Intratumoral positioning shaped distinct cDC1-like cell states, with DC-LAMP + CCR7 + migratory cDC1s nucleating niches enriched in CD4 + , CD8 + T cells, and B cells in mouse and human tumors.
How It Works, Simply
This immunology research focuses on T cells · Immune response · Genetics. Researchers evaluated it using an in vivo animal model (Preclinical discovery) at the preclinical stage of medical research.
3 Key Takeaways
Clinical Takeaways- 01Core Finding
Reprogrammed tumor cells into cDC1-like cells remodeled the tumor microenvironment and induced immunogenic TLSs (imgTLSs) across melanoma, colon, bladder, breast, and pancreatic cancer models with distinct genetic backgrounds. cDC1-like cells activated lymphotoxin, TNF, and interferon programs and engaged early with T cells through MHC class I and CD40 signaling to induce imgTLSs containing BCL6 + germinal centers, independently of endogenous cDC1s.
- 02Study Evidence
Tested in a in vivo animal model (preclinical discovery) at the preclinical stage.
- 03Practical Meaning
Early laboratory or animal model findings — human trials are still needed to confirm safety and benefit.
Biological Mechanism & Study Design
Study Design & Cohort
Animal models
In vivo animal model (Preclinical discovery) · Preclinical
Biological Pathway & Modality
T cells · Immune response · Genetics
Intervention: Tumor-to-dendritic cell reprogramming induces immunogenic lymphoid structures across
Experimental Findings & Endpoints
Tertiary lymphoid structures (TLSs) in tumors are associated with improved responses to immunotherapy.
Here, we examined the impact of type 1 conventional dendritic cells (cDC1s) in TLS formation. Reprogrammed tumor cells into cDC1-like cells remodeled the tumor microenvironment and induced immunogenic TLSs (imgTLSs) across melanoma, colon, bladder, breast, and pancreatic cancer models with distinct genetic backgrounds. cDC1-like cells activated lymphotoxin, TNF, and interferon programs and engaged early with T cells through MHC class I and CD40 signaling to induce imgTLSs containing BCL6 + germinal centers, independently of endogenous cDC1s.
Intratumoral positioning shaped distinct cDC1-like cell states, with DC-LAMP + CCR7 + migratory cDC1s nucleating niches enriched in CD4 + , CD8 + T cells, and B cells in mouse and human tumors.
Clinical Translation & Practice Context
ImgTLSs sustained B and T cell responses and promoted systemic immunity through expansion of shared clonotypes in distant, untreated tumors.
Our findings outline the spatial organization, signaling programs and interactions of cDC1-like cells that initiate intratumoral lymphoid structures and establish cellular reprogramming as a strategy toward overcoming resistance to immunotherapy.
The Bottom Line · Clinical Pearl
“Our findings outline the spatial organization, signaling programs and interactions of cDC1-like cells that initiate intratumoral lymphoid structures and establish cellular reprogramming as a strategy toward overcoming resistance to immunotherapy.”
Published in Immunity · Current Stage: Preclinical
